- Conditions
- Metastatic Castration-sensitive Prostate Cancer
- Interventions
- Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
- Combination Product · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 696 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 53
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 290
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone, Prednisone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
- Interventions
- TAVT-45, Zytiga, Prednisone
- Drug
- Lead sponsor
- Tavanta Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Cancer Of Prostate, Prostate Neoplasms
- Interventions
- PDS01ADC, Docetaxel, M7824, Prednisone, ADT
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 110 Years · Male only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
- Drug
- Lead sponsor
- Sun Pharmaceutical Industries Limited
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 17
- States / cities
- Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- PACE with Cabazitaxel (15 mg/m2), PACE with Cabazitaxel (20 mg/m2)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone acetate, Prednisone, Radium-223 dichloride, cabazitaxel, Carboplatin, Enzalutamide
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Bicalutamide, Leuprolide, Goserelin, Triptorelin, Docetaxel, Abiraterone, Apalutamide, Enzalutamide
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 21 Years to 85 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- BEZ235, BKM120
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Hackensack, New Jersey
- Conditions
- Prostate Cancer
- Interventions
- Abiraterone acetate, Androgen deprivation, Radiation Therapy, Prednisone
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 80 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT)
- Drug · Radiation
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Abiraterone acetate, Durvalumab, Methotrexate, Vinblastine, Doxorubicin Hydrochloride, Cisplatin
- Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Bloomington, Indiana • Houston, Texas
- Conditions
- Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
- Drug · Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Congenital Adrenal Hyperplasia
- Interventions
- Abiraterone acetate
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Bethesda, Maryland • Ann Arbor, Michigan + 1 more
- Conditions
- Prostate Cancer
- Interventions
- PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone
- Drug
- Lead sponsor
- Pellficure Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Omaha, Nebraska
- Conditions
- Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab
- Drug
- Lead sponsor
- Biosplice Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Aurora, Colorado • Scarborough, Maine + 11 more
- Conditions
- Metastatic Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- olaparib, abiraterone acetate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 23 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Denver, Colorado • Jacksonville, Florida + 15 more
- Conditions
- Prostate Cancer
- Interventions
- AR-v7 assays
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Baltimore, Maryland • New York, New York + 1 more
- Conditions
- Castration-Resistant Prostatic Neoplasms
- Interventions
- Cetrelimab 480 mg, Apalutamide 240 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- San Francisco, California • Shreveport, Louisiana • Ann Arbor, Michigan + 7 more
- Conditions
- Prostate Cancer
- Interventions
- EC1169, EC0652
- Drug · Other
- Lead sponsor
- Endocyte
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • New Orleans, Louisiana + 3 more
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
- Interventions
- Testosterone cypionate, Nivolumab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts